The efficacy was statistically significantly much higher, when the HER-2+ SK-BR-3 and the patients' HER-2+ breast cancer cells were treated with anti-HER-2001 × HBsAg, and anti-HER-2004 × HBsAg. The gene discussed is ERBB2; the disease is breast carcinoma.